Notizie

Le Temps (17.05.2021) - The wealth management sector in Switzerland, seen by some as traditionalist or even downright old-fashioned, has once again shown how its agility and innovativeness still make it the leader.

Raconteur (The Wealth Management 2021 report published in The Sunday Times - 16.05.2021) - The health of our planet is intimately linked to your pension and your long-term financial goals, says Victoria Leggett, Head of Impact Investing at UBP.

Finanz und Wirtschaft (19.01.2021) - Norman Villamin, Chief Investment Officer Wealth Management of Union Bancaire Privée, considers fears of significantly higher interest rates to be premature. He prefers mining to banking stocks.

Institutional Money (06.05.2021) - In recent months, nominal interest rates have increased globally. While this trend is expected to continue, the drivers of this move are likely to change, thereby affecting how investors position themselves in fixed-income markets.

Japan’s equity markets have outpaced other major developed market equities in both 2020 and year-to-date in 2021 as the world seeks to transition to a post-pandemic recovery.

Hubbis (03.04.2021) – Hubbis recently spoke with Michael Blake, CEO UBP Asia, as he cast his eye over the regional wealth management market and explained why he and UBP remain so optimistic about private banking in the region.

The first quarter of 2021 was positive for most asset classes. However, financial markets were far from calm.

We are introducing a new monthly podcast series on foreign exchange.

L'Agefi (23.04.2021) – Union Bancaire Privée is on a continuous growth trajectory integrating sustainability criteria. We interviewed Nicolas Faller, the bank’s Co-CEO Asset Management.

Asia Macro - China: Domestic demand takes over for the next leg of the recovery

PWM (08.04.2021) – Union Bancaire Privée’s Michael Blake discusses the importance of an integrated investment banking and wealth management model for servicing wealthy families

UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.